A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study

Journal article

Peer reviewed

J. Chan, W.E. Brady, J. Brown, M.S. Shahin, P.G. Rose, J.H. Kim, A.A. Secord, J.L. Walker and B.J. Monk

Gynecologic oncology, Vol.138, pp.3-3

05/01/2015

Metrics

4 Record Views

Title: A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study
Creators: J. Chan - California Pacific & Palo Alto Medical Foundation/Sutter Research Institute, San Francisco, CA, USA
W.E. Brady - Gynecologic Oncology Group
J. Brown - The University of Texas MD Anderson Cancer Center
M.S. Shahin - Abington Memorial Hospital
P.G. Rose - Cleveland Clinic
J.H. Kim - Yonsei University
A.A. Secord - Duke Medical Center
J.L. Walker - University of Oklahoma
B.J. Monk - Creighton University
Publication Details: Gynecologic oncology, Vol.138, pp.3-3
Publisher: Elsevier Inc
Identifiers: 991005969013902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article